# Phase 1/2 Urinary Bladder cancer trials: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials in phase 1/2 for Urinary Bladder cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Urinary Bladder cancer trials: 25 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/urinary-bladder-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 2, 2026 | NCT07800507 | Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer | Yunnan Cancer Hospital | Phase 1/2 | Not yet recruiting | NMIBC | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800507) |
| June 25, 2026 | NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer | Fred Hutchinson Cancer Center | Phase 1/2 | Recruiting | Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667335) |
| May 12, 2026 | NCT07579195 | Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial | University of Washington | Phase 1/2 | Recruiting | Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8 | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579195) |
| February 19, 2026 | NCT07421700 | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | Pfizer | Phase 1/2 | Recruiting | Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421700) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| January 14, 2026 | NCT07341737 | SL-28 for Advanced Solid Tumours | Second Life Therapeutics | Phase 1/2 | Recruiting | Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341737) |
| December 3, 2025 | NCT07261592 | Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1/2 | Not yet recruiting | Bladder Cancer, Histone Deacetylase Inhibitor, Entinostat, Chemotherapy | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07261592) |
| November 18, 2025 | NCT07232602 | KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial... | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Bladder Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07232602) |
| October 30, 2025 | NCT07222488 | A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Bladder Cancer, Urinary Bladder Neoplasms | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222488) |
| June 22, 2025 | NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | Tasca Therapeutics | Phase 1/2 | Recruiting | Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07030257) |
| May 4, 2025 | NCT06957561 | Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | Sun Yat-sen University | Phase 1/2 | Not yet recruiting | Bladder Cancer, Muscle-invasive Bladder Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06957561) |
| February 7, 2025 | NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors | University of Arizona | Phase 1/2 | Recruiting | Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06814496) |
| December 13, 2024 | NCT06732531 | Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer | Zhuhai Beihai Biotech Co., Ltd | Phase 1/2 | Recruiting | Bladder Cancer, Non Muscle Invasive | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06732531) |
| November 26, 2024 | NCT06704191 | In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial | Mayo Clinic | Phase 1/2 | Recruiting | Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage 0is... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06704191) |
| June 24, 2024 | NCT06470282 | Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer | University of California, San Francisco | Phase 1/2 | Recruiting | Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06470282) |
| May 1, 2024 | NCT06394570 | Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer | University of Texas Southwestern Medical Center | Phase 1/2 | Recruiting | Bladder Cancer | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06394570) |
| April 15, 2024 | NCT06364956 | Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1/2 | Recruiting | Bladder Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06364956) |
| April 2, 2024 | NCT06341400 | RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients | Zhujiang Hospital | Phase 1/2 | Recruiting | Bladder Cancer, Muscle-Invasive Bladder Carcinoma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06341400) |
| February 13, 2024 | NCT06255964 | A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 1/2 | Not yet recruiting | Bladder Cancer | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06255964) |
| July 13, 2023 | NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | Cancer Research UK | Phase 1/2 | Recruiting | Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05944237) |
| October 24, 2022 | NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid... | Marengo Therapeutics, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus... | 366 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05592626) |
| March 4, 2022 | NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or... | Aulos Bioscience, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05267626) |
| February 12, 2021 | NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | enGene, Inc. | Phase 1/2 | Recruiting | Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder... | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04752722) |
| January 26, 2021 | NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | Dana-Farber Cancer Institute | Phase 1/2 | Recruiting | Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04724018) |
| September 26, 2019 | NCT04106115 | DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr | University College, London | Phase 1/2 | Recruiting | Bladder Cancer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04106115) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| University of Texas Southwestern Medical Center | 1 |
| Yunnan Cancer Hospital | 1 |
| University College, London | 1 |
| Mayo Clinic | 1 |
| University of Washington | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| Essen Biotech | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Sun Yat-sen University | 1 |
| SUNHO（China）BioPharmaceutical CO., Ltd. | 1 |
| enGene, Inc. | 1 |
| Cancer Research UK | 1 |
| Dana-Farber Cancer Institute | 1 |
| University of Arizona | 1 |
| Tasca Therapeutics | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| Marengo Therapeutics, Inc. | 1 |
| Aulos Bioscience, Inc. | 1 |
| Zhuhai Beihai Biotech Co., Ltd | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Zhujiang Hospital | 1 |
| Second Life Therapeutics | 1 |
| University of California, San Francisco | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 8 |
| Spain | 5 |
| France | 4 |
| United Kingdom | 4 |
| Australia | 4 |
| Canada | 3 |
| Israel | 2 |
| Italy | 2 |
| Netherlands | 2 |
| South Korea | 2 |
| Austria | 1 |
| Belgium | 1 |
| Greece | 1 |
| Norway | 1 |
| Turkey (Türkiye) | 1 |
| Japan | 1 |
| Puerto Rico | 1 |
| Germany | 1 |
| Taiwan | 1 |
| Chile | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dim sum restaurants in the United States](https://specstream.ai/data/businesses/dim-sum-restaurants/united-states)
- [Road contractors in the United States](https://specstream.ai/data/businesses/road-contractors/united-states)
- [Electric utilities in the United States](https://specstream.ai/data/businesses/electric-utilities/united-states)
- [Sign makers in the United States](https://specstream.ai/data/businesses/sign-makers/united-states)
- [Ethiopian restaurants in the United States](https://specstream.ai/data/businesses/ethiopian-restaurants/united-states)
- [Stone and masonry companies in the United States](https://specstream.ai/data/businesses/stone-and-masonry-companies/united-states)
